Complement (C1q) Binding to HLA Antibodies in a Solid-phase Immunoassay and Clinical Effect on Platelet Transfusion
Condition(s):Thrombocytopenia; Platelet Transfusion RefractorinessLast Updated:March 21, 2024Completed
Hide Studies Not Open or Pending
Condition(s):Thrombocytopenia; Platelet Transfusion RefractorinessLast Updated:March 21, 2024Completed
Condition(s):ThrombocytopeniaLast Updated:October 7, 2009Completed
Condition(s):Lymphoma; Multiple Myeloma; Lymphocytic Leukemia; Hodgkin DiseaseLast Updated:October 2, 2017Completed
Condition(s):Poor Platelet Transfusion OutcomeLast Updated:April 1, 2015Completed
Condition(s):Leukemia; LymphomaLast Updated:August 2, 2012Terminated
Condition(s):Hemato-Oncologic Patients; Myelosuppression; ThrombocytopeniaLast Updated:February 27, 2007Completed
Condition(s):ThrombocytopeniaLast Updated:April 14, 2010Completed
Condition(s):Thrombocytopenia; Alloimmune Platelet RefractorinessLast Updated:January 3, 2019Completed
Condition(s):Aplastic Anemia; Platelet Transfusion RefractorinessLast Updated:April 27, 2023Recruiting
Condition(s):Thrombocytopenia; Hematologic MalignancyLast Updated:July 13, 2023Enrolling by invitation
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.